San Diego-primarily based Viking Therapeutics marked alone as a serious competitor within the weight loss drug sector in February right after revealing promising facts from a mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified to be a weekly injection and in March the co